PMID- 7834211
OWN - NLM
STAT- MEDLINE
DCOM- 19950301
LR  - 20190512
IS  - 0007-1188 (Print)
IS  - 0007-1188 (Linking)
VI  - 113
IP  - 2
DP  - 1994 Oct
TI  - Characterization of prostanoid receptors on rat neutrophils.
PG  - 581-7
AB  - 1. The effects of various prostanoid agonists have been compared on the increase 
      in intracellular free calcium ([Ca2+]i) and the aggregation reaction of rat 
      peritoneal neutrophils induced by N-formyl-L-methionyl-L-leucyl-L-phenylalanine 
      (FMLP). 2. Prostaglandin E2 (PGE2) and the specific IP-receptor agonist, 
      cicaprost, both inhibited the FMLP-induced increase in [Ca2+]i (IC50 33 nM and 18 
      nM respectively) and the FMLP-induced aggregation reaction (IC50 5.6 nM and 7.9 
      nM respectively). PGD2, PGF2 alpha, and the TP-receptor agonist, U 46619, were 
      inactive at the highest concentration tested (1 microM). 3. The EP1-receptor 
      agonist, 17-phenyl-omega-trinor PGE2, and the EP3-receptor agonists, GR 63799X 
      and sulprostone, had no inhibitory effect on FMLP-stimulated rat neutrophils. 4. 
      PGE1 (EP/IP-receptor agonist) and iloprost (IP-receptor agonist) inhibited the 
      FMLP-induced increase in [Ca2+]i with IC50 values of 34 nM and 38 nM 
      respectively. The EP2-receptor agonists, butaprost and misoprostol (1 microM), 
      inhibited both FMLP-stimulated [Ca2+]i and aggregation. However another 
      EP2-receptor agonist, AH 13205, was inactive in both assays. 5. Prostanoid 
      receptors present on rat neutrophils were further characterized by measuring 
      [3H]-adenosine 3':5'-cyclic monophosphate ([3H]-cyclic AMP) accumulation. Only 
      those agonists capable of stimulating [3H]-cyclic AMP accumulation were able to 
      inhibit both FMLP-stimulated [Ca2+]i and aggregation. 6. These results indicate 
      that rat neutrophils possess inhibitory IP and EP-receptors; the relative 
      potencies of PGE2, misoprostol and butaprost are those expected for the 
      EP2-receptor subtype. No evidence for DP, FP, TP or EP1 and EP3-receptors was 
      obtained.
FAU - Wise, H
AU  - Wise H
AD  - Department of Pharmacology, Faculty of Medicine, Chinese University of Hong Kong, 
      Shatin, New Territories.
FAU - Jones, R L
AU  - Jones RL
LA  - eng
PT  - Journal Article
PT  - Research Support, Non-U.S. Gov't
PL  - England
TA  - Br J Pharmacol
JT  - British journal of pharmacology
JID - 7502536
RN  - 0 (Prostaglandin Antagonists)
RN  - 0 (Prostaglandins, Synthetic)
RN  - 0 (Receptors, Prostaglandin)
RN  - 59880-97-6 (N-Formylmethionine Leucyl-Phenylalanine)
RN  - E0399OZS9N (Cyclic AMP)
RN  - SY7Q814VUP (Calcium)
SB  - IM
MH  - Animals
MH  - Calcium/metabolism
MH  - Cell Aggregation/drug effects
MH  - Cyclic AMP/biosynthesis
MH  - In Vitro Techniques
MH  - Male
MH  - N-Formylmethionine Leucyl-Phenylalanine
MH  - Neutrophils/*drug effects/metabolism
MH  - Prostaglandin Antagonists/pharmacology
MH  - Prostaglandins, Synthetic/pharmacology
MH  - Rats
MH  - Rats, Sprague-Dawley
MH  - Receptors, Prostaglandin/agonists/antagonists & inhibitors/*drug effects
PMC - PMC1510101
EDAT- 1994/10/01 00:00
MHDA- 1994/10/01 00:01
PMCR- 1995/10/01
CRDT- 1994/10/01 00:00
PHST- 1994/10/01 00:00 [pubmed]
PHST- 1994/10/01 00:01 [medline]
PHST- 1994/10/01 00:00 [entrez]
PHST- 1995/10/01 00:00 [pmc-release]
AID - 10.1111/j.1476-5381.1994.tb17029.x [doi]
PST - ppublish
SO  - Br J Pharmacol. 1994 Oct;113(2):581-7. doi: 10.1111/j.1476-5381.1994.tb17029.x.